Editor's note: This is the first story in a two-part series on the medtech IPO landscape. You can read the second story on how to take a company public here .

When Ceribell went public in October, the window for medtech initial public offerings was open just a crack — if not shut completely.

Ceribell, which develops technology to diagnose patients with neurological disorders, led a rush of public offerings activity in just a few months, breaking a three-year drought in IPOs. The new public offerings prompted questions about whether the medical device industry could have another IPO moment after a 2021 spike.

“At that time, we debated potentially being the first med device IPO in a few years,” Ceribell CFO Scott Blumberg said in an emailed statement. “Initially we, and I think a number

See Full Page